Illumina, Sequenom settle suit

Illumina Inc. (NASDAQ:ILMN) said it will pay $50 million to Sequenom Inc. (NASDAQ:SQNM) to settle ongoing patent infringement claims related to the companies' nucleic acid analysis technologies for non-invasive prenatal testing (NIPT).

Sequenom CFO Carolyn Beaver told BioCentury the companies will create a shared pool of more than 400 patents and patent applications. Beaver said both companies will have the right to use the patents to make laboratory developed tests (LDTs) for NIPT, while Illumina will have exclusive worldwide rights to develop and sell in vitro diagnostic kits and to license the IP to third parties. ...